

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司 \***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

## **INSIDE INFORMATION**

### **COMPLETION OF DISPOSAL OF SHARES BY A CONTROLLING SHAREHOLDER**

Reference is made to the announcement of Genscript Biotech Corporation (the “**Company**”) dated 14 May 2021 in relation to the disposal of shares by a controlling shareholder and the supplemental announcement of the Company dated 7 June 2021 in relation to the aforementioned announcement (collectively, the “**Announcements**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

This announcement is made by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

### **COMPLETION OF DISPOSAL OF SHARES BY A CONTROLLING SHAREHOLDER**

The Company has been informed by GS Corp that it completed the sale of 61,789,112 Shares to the Purchaser on 11 June 2021 pursuant to the agreement relating to the Disposal.

### **EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY**

The table below sets out a summary of the shareholding structure of the Company (i) before the completion of the Disposal; (ii) as at the date of this announcement, following the completion of the Disposal; and (iii) after the completion of the Disposal and issuance of the RSA Shares B (assuming there is no change in the issued share capital of the Company since the date of this announcement save for the issuance of the RSA Shares B).

Shareholders	Before the completion of the Disposal		As at the date of this announcement and following the completion of the Disposal		Immediately after this announcement and following the completion of the Disposal and issuance of the RSA Shares B <sup>(Note 2)</sup> (assuming there is no change in the issued share capital of the Company since the date of this announcement save for the issuance of the RSA Shares B <sup>(Note 2)</sup>	
	Number of Shares held	%	Number of Shares held	%	Number of Shares held	%
Genscript Corporation <sup>(Note 1)</sup>	871,366,235	42.16%	809,577,123	39.17%	809,577,123	39.06%
GNS Holdings Limited	102,981,853	4.98%	164,770,965	7.97%	164,770,965	7.95%
Other shareholders	1,092,430,305	52.86%	1,092,430,305	52.86%	1,098,287,179	52.99%
<b>Total issued Shares</b>	<b><u>2,066,778,393</u></b>	<b><u>100.00</u></b>	<b><u>2,066,778,393</u></b>	<b><u>100.00</u></b>	<b><u>2,072,635,267</u></b>	<b><u>100.00</u></b>

*Note:*

1. Genscript Corporation is a company incorporated in the State of Delaware in the U.S. and owned as to approximately 37.47%, approximately 3.66%, approximately 22.76%, approximately 7.96%, approximately 2.07%, approximately 0.70%, approximately 0.42%, approximately 0.42%, approximately 11.10%, approximately 10.26%, approximately 1.95%, approximately 1.05% and approximately 0.18% by Zhang Fangliang, the Zhang Trust, Wang Luquan, Wu Yongmei, the Wu 2017 Trust, the Wu 2019 Trust, the Wu 2020 Separate Trust A, the Wu 2020 Separate Trust B, the Wu 2020 Trust, Wang Ye, the Wang Trust, Mu Yingjun and Charity B, respectively.
2. For the issuance of the RSA Shares B, please refer to the announcement of the Company dated 1 June 2021 in relation to, among others, the issuance of the 5,856,874 RSA Shares B. As of the date of this announcement, such Shares have not been issued and allotted.

By order of the Board  
**GenScript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 11 June 2021

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* For identification purposes only